The drug’s pink coloring can fade over the course of its two-year shelf life, which can be confusing to patients. The FDA is requiring BioDelivery Sciences International to make formulation changes in Onsolis to prevent the color change over time. There are no safety issues noted with the drug.
Packages of Onsolis currently on shelves can still be used for pain treatment in cancer patients, but until the BDSI complies with the FDA’s manufacturing requirement, no new product will be made or shipped.
Related Articles on Pain Management:
5 Pain Management Physicians Discuss Urine Drug Testing
Physical Therapy Center Launches New Patient Education Website
Osteoarthritis Painkillers May Resume Trials Despite Joint Damage Risks
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
